Diabetologie und Stoffwechsel 2021; 16(S 01): S4-S5
DOI: 10.1055/s-0041-1727304
01. Klinische Diabetologie

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

Authors

  • LE Garcia-Pérez

    1   Lilly, S.A., Medical, Alcobendas, Spain

  • H Sapin

    2   Lilly France SAS, Medical, Neuilly Sur Seine, France

  • K Norrbacka

    3   Eli Lilly and Company, Medical, Helsinki, Finland

  • B Guerci

    4   Hôpital Brabois Adultes, Medical, CHRU de Nancy, France

  • F Giorgino

    5   University of Bari, Medical, Aldo Moro, Italy

  • U Aigner

    6   Versdias GmbH, Medical, Sulzbach-Rosenberg, Germany

  • MO Federici

    7   Eli Lilly Company Italia SpA, Medical, Florence, Italy

  • R Gentilella

    8   Former employee of Eli Lilly Company Italia SpA, Medical, Florence, Italy

  • E Heitmann

    9   Lilly Deutschland GmbH, Medical, Bad Homburg, Germany

  • H Jung

    9   Lilly Deutschland GmbH, Medical, Bad Homburg, Germany

  • M Rosilio

    2   Lilly France SAS, Medical, Neuilly Sur Seine, France

  • K Boye

    10   Eli Lilly and Company, Medical, Indianapolis, United States
Further Information
Also available at
 
 

Objective Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are usually recommended as first injectable therapy for type 2 diabetes (T2D). Randomized clinical trials are standard for assessing efficacy and safety, observational studies are valuable to understand GLP-1RA use in clinical practice. Methods: TROPHIES is a 24-month, prospective, observational study in France, Germany, Italy in adult patients with T2 D initiating first injectable glucose-loweringtreatment with once-weekly dulaglutide / once-daily liraglutide. The primary outcome, time on first GLP-1RA without significant treatment change due to T2D-related factors, was defined as discontinuation of this GLP-1RA/intensification of glucose-lowering treatment. At baseline, demographics, T2 D duration, HbA1c levels, reported HbA1c targets, pre-existing diabetes-related diagnoses and concomitantly used oral glucose-lowering medications were assessed. Results: To date, data from 2065 patients initiating dulaglutide (1089) or liraglutide (976) are analyzed. For patients initiating dulaglutide or liraglutide, mean age 58.9 and 59.4yr, 55.3 % and 57.4 % were male, with mean duration of T2 D 8.7 and 8.3yr, and mean BMI 33.8 and 34.1kg/m2, respectively. Mean baseline HbA1c level 8.2 % (dulaglutide) and 8.3 % (liraglutide) exceeded reported mean HbA1c target 6.9 %. Macrovascular and microvascular diabetes related conditions were reported in 8.2 % and 17.7 % (dulaglutide) and 11.5 % and 15.5 % (liraglutide) patients, respectively. Of patients initiating dulaglutide or liraglutide, 27.5 % and 25.5 % had taken ≥2 concomitant oral glucose-lowering medications, respectively, biguanides being most common. Conclusion: In both groups, BMI reflected obesity. HbA1c levels exceeded reported targets justifying treatment intensification with GLP-1RA after ~8.5yr of diabetes. This study helps understand profiles of patients being prescribed dulaglutide or liraglutide in France, Germany, Italy.


Interessenskonflikt

1. Angestellte der Lilly Deutschland GmbH

3. Besitz von Firmenaktien

6. Sponsor: Eli Lilly & Company

Publication History

Article published online:
06 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany